biologics Archives - Insights From Our Labs to Yours

Bioanalysis of Biologics: Understanding the Role of LC-MS

by Labcorp Drug Developmentupdated on Tuesday, June 8, 2021Wednesday, December 9, 2020

As biologics-based therapies have expanded, LC-MS is increasingly applied to support quantitative bioanalysis to detect diverse peptides and proteins. LC-MS can offer a few notable advantages compared to the traditional approach for quantification with ligand-binding assays (LBAs), but is typically thought of as a complementary approach.

Establishing Control Over the Manufacturing Process and the Quality of your Biologic

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Tuesday, February 13, 2018

When a patient reads the label on their medicine bottle, he or she naturally relies on the medicine to contain the correct drug, be safe, work as intended and list the correct dosage. The pharmaceutical companies that produce these medicines similarly must rely on their internal manufacturing processes and quality control …

Regional Availability of and Reimbursement Models for Biologic Therapies to Treat RA Patients with Moderate to Severe Disease

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Monday, September 18, 2017

Rheumatoid arthritis (RA) is an autoimmune disease primarily affecting the musculoskeletal system with typical symptoms including swollen and painful joints, joint stiffness and loss of function, ultimately leading to disability if untreated. RA also has significant systemic features in many patients that appreciably impact upon their quality of life, including …

ELISPOT Assay: A Powerful Tool in Vaccine Development and Immune Monitoring

by Sinnathamby Gomathinayagam, Ph.D.updated on Thursday, May 20, 2021Thursday, June 1, 2017

Over the past several years, the scientific community has made tremendous progress in advancing our understanding of the immune system, from the basic functions of its various components to molecular pathways that operate within those components. With new, state-of-the-art tools and technologies, immunologists now have the ability to better understand the …

Quantifying in vivo Biodistribution and Kinetics of Your Biologic or Nanomaterial

by Labcorp Drug Developmentupdated on Thursday, April 22, 2021Tuesday, November 17, 2015

With the ability to provide non-invasive, three dimensional, longitudinal, and quantitative data—PET, SPECT, and fluorescence imaging (FMT) enable translational imaging of: Biodistribution Targeting Kinetics Clearance Pathways